应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。
关闭
BMY 施贵宝
已收盘 12-17 16:00:00 EST
53.55
-0.68
-1.25%
盘后
53.57
+0.02
+0.04%
19:57 EST
最高
54.49
最低
53.50
成交量
1,499万
今开
54.07
昨收
54.23
日振幅
1.83%
总市值
1,090亿
流通市值
1,088亿
总股本
20.36亿
成交额
8.08亿
换手率
0.74%
流通股本
20.32亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
数据加载中...
北京优虎网络科技有限公司
资讯
新帖
简况
施贵宝加拿大欢迎CDA对Opdivo®与Yervoy®联合用于MSI-H/DMMR转移性结直肠癌的一线治疗的积极推荐
美股速递 · 12-17 20:07
施贵宝加拿大欢迎CDA对Opdivo®与Yervoy®联合用于MSI-H/DMMR转移性结直肠癌的一线治疗的积极推荐
港股异动 | 和铂医药-B(02142)仍跌2% 与百时美施贵宝达成全球战略合作 潜在收益超10亿美元
智通财经 · 12-17 09:59
港股异动 | 和铂医药-B(02142)仍跌2% 与百时美施贵宝达成全球战略合作 潜在收益超10亿美元
和铂医药-B与施贵宝达成全球战略合作与许可协议
投资观察 · 12-17 09:32
和铂医药-B与施贵宝达成全球战略合作与许可协议
美银上调施贵宝目标价至61美元
格隆汇 · 12-16 16:46
美银上调施贵宝目标价至61美元
施贵宝：Bofa全球研究将评级从中性上调至买入；目标价由52美元上调至61美元
美股速递 · 12-15 19:55
施贵宝：Bofa全球研究将评级从中性上调至买入；目标价由52美元上调至61美元
2025年平均回报近28%！2026年《巴伦》选股：亚马逊及另外9只股值得买入
老虎资讯综合 · 12-15 16:27
2025年平均回报近28%！2026年《巴伦》选股：亚马逊及另外9只股值得买入
产业新闻 | FDA授予百时美施贵宝PD-1疗法组合优先审评资格；创新帕金森病免疫疗法积极试验结果公布
药明康德 · 12-12
产业新闻 | FDA授予百时美施贵宝PD-1疗法组合优先审评资格；创新帕金森病免疫疗法积极试验结果公布
美国食品药品监督管理局（FDA）对施贵宝Opdivo®（Nivolumab）联合化疗治疗经典型霍奇金淋巴瘤的申请给予优先审评
美股速递 · 12-11
美国食品药品监督管理局（FDA）对施贵宝Opdivo®（Nivolumab）联合化疗治疗经典型霍奇金淋巴瘤的申请给予优先审评
富国银行上调施贵宝目标价至55美元
中金财经 · 12-11
富国银行上调施贵宝目标价至55美元
Biontech与施贵宝公布Pumitamig全球二期研究数据
投资观察 · 12-09
Biontech与施贵宝公布Pumitamig全球二期研究数据
BioNTech Se：Pumitamig联合化疗在所有四种化疗方案中的安全性均可控
美股速递 · 12-09
BioNTech Se：Pumitamig联合化疗在所有四种化疗方案中的安全性均可控
美股异动 | 百时美施贵宝(BMY.US)涨5% 公司将继续阿尔茨海默病研究
智通财经 · 12-03
美股异动 | 百时美施贵宝(BMY.US)涨5% 公司将继续阿尔茨海默病研究
施贵宝股价在盘前上涨3.4%，继续招募阿尔茨海默病药物试验患者
美股速递 · 12-03
施贵宝股价在盘前上涨3.4%，继续招募阿尔茨海默病药物试验患者
百时美施贵宝将继续推进阿尔茨海默病药物三期临床研究
格隆汇 · 12-03
百时美施贵宝将继续推进阿尔茨海默病药物三期临床研究
施贵宝宣布继续进行针对阿尔茨海默病相关精神病的Adept-2三期研究
美股速递 · 12-03
施贵宝宣布继续进行针对阿尔茨海默病相关精神病的Adept-2三期研究
施贵宝CEO Boerner：施贵宝预计在英美制药交易后未来5年将能够投资超过5亿美元
美股速递 · 12-01
施贵宝CEO Boerner：施贵宝预计在英美制药交易后未来5年将能够投资超过5亿美元
施贵宝在2025年ASH大会上展示血液学管线潜力，推动下一代产品组合的动能
美股速递 · 12-01
施贵宝在2025年ASH大会上展示血液学管线潜力，推动下一代产品组合的动能
四川百利天恒表示仍有资格获得高达2.5亿美元的短期付款，以及在达到特定研发、监管、商业里程碑后获得高达71亿美元的额外付款
美股速递 · 11-30
四川百利天恒表示仍有资格获得高达2.5亿美元的短期付款，以及在达到特定研发、监管、商业里程碑后获得高达71亿美元的额外付款
百利天恒宣布其子公司近期已从施贵宝获得2.5亿美元里程碑付款，涉及Iza-Bren全球战略协议
美股速递 · 11-30
百利天恒宣布其子公司近期已从施贵宝获得2.5亿美元里程碑付款，涉及Iza-Bren全球战略协议
百利天恒(688506.SH)子公司收到与百时美施贵宝就iza-bren项目里程碑付款2.5亿美元
智通财经 · 11-30
百利天恒(688506.SH)子公司收到与百时美施贵宝就iza-bren项目里程碑付款2.5亿美元
暂无数据
公司概况
公司名称：
施贵宝
所属市场：
NYSE
上市日期：
--
主营业务：
百时美施贵宝公司于1933年8月根据特拉华州法律注册成立，名为百时美公司，继承了1887年在纽约成立的一家企业。1989年，由于合并，公司更名为百时美施贵宝公司。该公司在全球范围内从事生物制药产品的发现、开发、许可、制造、营销、分销和销售。该公司预计，对Celgene和MyoKardia的收购将进一步将公司定位为领先的生物制药公司，通过几项近期资产和额外的外部合作伙伴关系扩大其肿瘤学、血液学、免疫学和心血管领域的投资组合。
发行价格：
--
{"stockData":{"symbol":"BMY","market":"US","secType":"STK","nameCN":"施贵宝","latestPrice":53.55,"timestamp":1766005200000,"preClose":54.23,"halted":0,"volume":14990510,"hourTrading":{"tag":"盘后","latestPrice":53.5726,"preClose":53.55,"latestTime":"19:57 EST","volume":2757945,"amount":147688494.2664,"timestamp":1766019477731},"delay":0,"floatShares":2031646263,"shares":2035753027,"eps":2.970486,"marketStatus":"已收盘","change":-0.68,"latestTime":"12-17 16:00:00 EST","open":54.07,"high":54.49,"low":53.495,"amount":807509392.3004,"amplitude":0.018348,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":2.970486,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1766048400000},"marketStatusCode":5,"adr":0,"adrRate":0,"listingDate":-18475200000,"exchange":"NYSE","adjPreClose":54.23,"dividendRate":0.046332,"preHourTrading":{"tag":"盘前","latestPrice":54.16,"preClose":54.23,"latestTime":"09:29 EST","volume":483479,"amount":26221115.154002,"timestamp":1765981770069},"postHourTrading":{"tag":"盘后","latestPrice":53.5726,"preClose":53.55,"latestTime":"19:57 EST","volume":2757945,"amount":147688494.2664,"timestamp":1766019477731},"volumeRatio":0.92719,"impliedVol":0.2755,"impliedVolPercentile":0.096},"requestUrl":"/m/hq/s/BMY/tweets","defaultTab":"tweets","newsList":[{"id":"1146684068","title":"施贵宝加拿大欢迎CDA对Opdivo®与Yervoy®联合用于MSI-H/DMMR转移性结直肠癌的一线治疗的积极推荐","url":"https://stock-news.laohu8.com/highlight/detail?id=1146684068","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1146684068?lang=zh_cn&edition=full","pubTime":"2025-12-17 20:07","pubTimestamp":1765973241,"startTime":"0","endTime":"0","summary":"施贵宝加拿大欢迎CDA对Opdivo®与Yervoy®联合用于MSI-H/DMMR转移性结直肠癌的一线治疗的积极推荐","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0882574055.USD","LU0985481810.HKD","LU1670711123.USD","LU1718418525.SGD","LU1093756168.USD","BMY","LU0306806265.USD","LU1261432733.SGD","LU1670711040.USD","LU2242652126.USD","LU1571399168.USD","LU1323610961.USD","LU1868836757.USD","IE00BJJMRZ35.SGD","LU1074936037.SGD","IE00BFTCPJ56.SGD","BK4007","LU2133065610.SGD","LU0225771236.USD","BK4588","LU2125154778.USD","IE00BFXG1179.USD","LU0868494617.USD","LU1868837300.USD","LU1989771016.USD","LU0321505439.SGD","LU0061475181.USD","IE0002141913.USD","LU0237698245.USD","BK4532","BK4534","LU0267386448.USD","LU1670710661.SGD","LU1868837136.USD","LU2242646821.SGD","LU1093756325.SGD","LU1585245621.USD","IE00BJT1NW94.SGD","LU0306807586.USD","LU1868836591.USD","BK4559","LU2360032135.SGD","BK4581","LU0114720955.EUR","LU1032466523.USD","LU1868836914.USD","LU1430594728.SGD","LU1291159041.SGD","IE0009355771.USD","IE00B2B36J28.USD","LU1670710588.SGD","BK4585","LU2125154935.USD","IE00BSNM7G36.USD","LU0321505868.SGD","LU0456855351.SGD","LU0096364046.USD","LU0225284248.USD"],"gpt_icon":0},{"id":"2592526179","title":"港股异动 | 和铂医药-B(02142)仍跌2% 与百时美施贵宝达成全球战略合作 潜在收益超10亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592526179","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592526179?lang=zh_cn&edition=full","pubTime":"2025-12-17 09:59","pubTimestamp":1765936773,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，和铂医药-B(02142)小幅高开后走低，一度跌超5%，现跌幅收窄。截至发稿，跌2.08%，报12.72港元，成交额3645.09万港元。消息面上，和铂医药今早宣布，与百时美施贵宝达成长期全球战略合作及许可协议，双方将共同研发新一代多特异性抗体疗法。根据协议条款，和铂医药将与百时美施贵宝合作推进及加速多特异性抗体发现项目。和铂医药将获得总计9000万美元的付款，若百时美施贵宝选择推进所有潜在项目，和铂医药还可获得高达10.35亿美元的开发及商业里程碑付款，以及基于未来产品净销售额的分级特许权使用费。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1382422.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","LU1670711123.USD","LU1670710588.SGD","LU2242646821.SGD","BK1574","LU1093756168.USD","LU1670710661.SGD","LU2242652126.USD","LU0225284248.USD","LU0237698245.USD","IE00B2B36J28.USD","BK4534","LU1868836591.USD","IE00BJT1NW94.SGD","BK1161","LU0321505439.SGD","BK4581","LU0882574055.USD","LU1291159041.SGD","LU1868837136.USD","LU1323610961.USD","LU1868836757.USD","LU1571399168.USD","LU1868836914.USD","LU2125154778.USD","LU2360032135.SGD","BMY","IE00BSNM7G36.USD","LU0114720955.EUR","LU0306806265.USD","LU1032466523.USD","LU2125154935.USD","BK4532","LU0225771236.USD","LU0321505868.SGD","LU1718418525.SGD","LU1585245621.USD","LU0456855351.SGD","BK4588","LU0985481810.HKD","LU1261432733.SGD","LU1093756325.SGD","IE0002141913.USD","02142","LU0061475181.USD","IE00BJJMRZ35.SGD","LU0306807586.USD","IE00BFXG1179.USD","LU1868837300.USD","IE00BFTCPJ56.SGD"],"gpt_icon":0},{"id":"1117376540","title":"和铂医药-B与施贵宝达成全球战略合作与许可协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1117376540","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117376540?lang=zh_cn&edition=full","pubTime":"2025-12-17 09:32","pubTimestamp":1765935166,"startTime":"0","endTime":"0","summary":"12月17日（路透社）- 和铂医药-B <2142.HK>::*与施贵宝达成全球战略合作与许可协议*可能将获得总额9000万美元的支付，以及最高达10.35亿美元的发展和商业里程碑*根据协议，双方将合作推进和加速多特异性抗体发现项目*","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1989771016.USD","LU0321505439.SGD","LU1868836914.USD","BK4588","LU0114720955.EUR","LU1093756325.SGD","BK4585","LU1868836757.USD","LU1868837300.USD","LU0225771236.USD","LU1074936037.SGD","BK4581","LU0868494617.USD","LU1261432733.SGD","LU0306806265.USD","LU0096364046.USD","LU0456855351.SGD","LU0225284248.USD","IE00BJT1NW94.SGD","LU1585245621.USD","LU2125154935.USD","BK4532","LU0237698245.USD","LU1868837136.USD","IE00BJJMRZ35.SGD","LU0267386448.USD","LU0306807586.USD","LU0882574055.USD","IE00BSNM7G36.USD","LU2125154778.USD","LU0061475181.USD","IE0002141913.USD","BMY","BK4534","LU0985481810.HKD","LU1093756168.USD","BK1583","BK4559","IE00BFTCPJ56.SGD","02142","LU1323610961.USD","LU0321505868.SGD","LU1670710661.SGD","BK1574","LU2133065610.SGD","LU2242646821.SGD","IE00B2B36J28.USD","IE00BFXG1179.USD","BK1161","BK4007","LU1430594728.SGD","LU1670711040.USD","IE0009355771.USD","LU1032466523.USD","LU1670711123.USD","LU1718418525.SGD","LU2242652126.USD","LU1670710588.SGD","LU2360032135.SGD","LU1291159041.SGD","LU1571399168.USD","LU1868836591.USD"],"gpt_icon":0},{"id":"2591022536","title":"美银上调施贵宝目标价至61美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2591022536","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591022536?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:46","pubTimestamp":1765874784,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK4532","LU0306807586.USD","LU1074936037.SGD","LU1989771016.USD","LU1093756325.SGD","LU0225771236.USD","LU1670711040.USD","LU0225284248.USD","LU0061475181.USD","LU0267386448.USD","LU1291159041.SGD","IE0009355771.USD","LU1323610961.USD","IE00BSNM7G36.USD","BMY","LU2242652126.USD","BK4534","LU1868837136.USD","LU2360032135.SGD","IE0002141913.USD","LU0114720955.EUR","LU1430594728.SGD","LU0868494617.USD","IE00BJJMRZ35.SGD","LU1868836757.USD","LU1868837300.USD","LU2125154935.USD","BK4007","LU1571399168.USD","LU2125154778.USD","IE00BJT1NW94.SGD","LU0096364046.USD","LU0306806265.USD","LU1670711123.USD","IE00BFXG1179.USD","LU1585245621.USD","LU1868836591.USD","LU1093756168.USD","LU2133065610.SGD","LU1670710661.SGD","LU1670710588.SGD","LU0321505439.SGD","LU2242646821.SGD","LU0985481810.HKD","LU0321505868.SGD","LU1718418525.SGD","LU0882574055.USD","IE00B2B36J28.USD","LU1032466523.USD","LU1868836914.USD"],"gpt_icon":0},{"id":"1103261588","title":"施贵宝：Bofa全球研究将评级从中性上调至买入；目标价由52美元上调至61美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1103261588","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103261588?lang=zh_cn&edition=full","pubTime":"2025-12-15 19:55","pubTimestamp":1765799723,"startTime":"0","endTime":"0","summary":"施贵宝：Bofa全球研究将评级从中性上调至买入；目标价由52美元上调至61美元","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","LU1093756325.SGD","LU1868836591.USD","IE0002141913.USD","IE0009355771.USD","LU1670711123.USD","LU1868836757.USD","LU0306807586.USD","LU1670711040.USD","IE00B2B36J28.USD","LU1074936037.SGD","LU0267386448.USD","BK4585","BK4581","LU0114720955.EUR","LU2125154778.USD","LU0225284248.USD","BK4532","LU1430594728.SGD","LU0225771236.USD","LU0321505868.SGD","LU2360032135.SGD","LU1323610961.USD","LU2242652126.USD","LU1670710661.SGD","BMY","LU2242646821.SGD","LU0985481810.HKD","LU1670710588.SGD","LU1093756168.USD","LU2125154935.USD","LU0882574055.USD","LU1571399168.USD","LU1261432733.SGD","LU1868836914.USD","LU0456855351.SGD","LU1868837300.USD","IE00BJT1NW94.SGD","LU0306806265.USD","LU1032466523.USD","LU1868837136.USD","LU0096364046.USD","IE00BJJMRZ35.SGD","IE00BSNM7G36.USD","LU0868494617.USD","LU1718418525.SGD","BK4534","BK4007","LU0321505439.SGD","LU2133065610.SGD","LU1291159041.SGD","LU1989771016.USD","BK4588","LU1585245621.USD","LU0061475181.USD","IE00BFTCPJ56.SGD","IE00BFXG1179.USD","LU0237698245.USD"],"gpt_icon":0},{"id":"1145596562","title":"2025年平均回报近28%！2026年《巴伦》选股：亚马逊及另外9只股值得买入","url":"https://stock-news.laohu8.com/highlight/detail?id=1145596562","media":"老虎资讯综合","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145596562?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:27","pubTimestamp":1765787221,"startTime":"0","endTime":"0","summary":"要点速览标普500指数在2025年上涨近20%，此前在2023年和2024年均录得约25%的回报。《巴伦周刊》2025年的选股（含分红）平均回报接近28%，显著跑赢标普500指数的15%。回顾：2025年是非常好的一年《巴伦周刊》在2025年挑选的10只股票整体跑赢了标普500指数。亚马逊目前股价约232美元，2025年仅上涨约6%，按2026年预期每股收益8美元计算，市盈率约29倍，相比增长更慢、却交易在38倍市盈率的沃尔玛，估值明显偏低。","market":"us","thumbnail":"https://static.tigerbbs.com/7cb476950a20a27b5d4b430bcabd040e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/7cb476950a20a27b5d4b430bcabd040e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"dc41550f5bb7b11827b30281f97c4f1b","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["DIS","MSGS","CMCSA","FLUT","FRFHF","AMZN","BMY","SLG","V","XOM"],"gpt_icon":1},{"id":"2590504741","title":"产业新闻 | FDA授予百时美施贵宝PD-1疗法组合优先审评资格；创新帕金森病免疫疗法积极试验结果公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2590504741","media":"药明康德","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590504741?lang=zh_cn&edition=full","pubTime":"2025-12-12 08:00","pubTimestamp":1765497601,"startTime":"0","endTime":"0","summary":"FDA授予百时美施贵宝PD-1疗法组合优先审评资格百时美施贵宝今日宣布，美国FDA已受理Opdivo的补充生物制品许可申请，用于与多柔比星、长春花碱和达卡巴嗪联合，治疗既往未接受治疗的III期或IV期经典型霍奇金淋巴瘤成人及儿童患者。FDA授予该申请优先审评资格，并将PDUFA日期确定为2026年4月8日。此次FDA受理及优先审评的决定，主要基于3期SWOG S1826研究的积极结果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212092546a443889e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251212092546a443889e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["IE0002141913.USD","LU1868836591.USD","BK4023","LU0096364046.USD","IE00B2B36J28.USD","LU1868836757.USD","IE00BJT1NW94.SGD","IE00BJJMRZ35.SGD","LU1718418525.SGD","BK4585","LU2360032135.SGD","IE00BFXG1179.USD","LU1670711040.USD","BK4007","BK4534","IE00BFTCPJ56.SGD","LU1571399168.USD","LU0985481810.HKD","LU0456855351.SGD","LU1323610961.USD","LU1670710588.SGD","BK4588","LU1261432733.SGD","LU1868837136.USD","LU1291159041.SGD","LU0868494617.USD","LU1032466523.USD","LU0267386448.USD","LU0321505868.SGD","PD","LU1670711123.USD","LU2242646821.SGD","IE0009355771.USD","BK4532","LU0321505439.SGD","LU1169590202.USD","LU2133065610.SGD","LU1585245621.USD","IE00BSNM7G36.USD","LU2242652126.USD","LU1093756325.SGD","LU1989771016.USD","LU1868837300.USD","LU1169589451.USD","BK4581","LU0114720955.EUR","LU2125154935.USD","BMY","LU0882574055.USD","LU1430594728.SGD"],"gpt_icon":0},{"id":"1172575849","title":"美国食品药品监督管理局（FDA）对施贵宝Opdivo®（Nivolumab）联合化疗治疗经典型霍奇金淋巴瘤的申请给予优先审评","url":"https://stock-news.laohu8.com/highlight/detail?id=1172575849","media":"美股速递","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1172575849?lang=zh_cn&edition=full","pubTime":"2025-12-11 19:59","pubTimestamp":1765454366,"startTime":"0","endTime":"0","summary":"美国食品药品监督管理局（FDA）对施贵宝Opdivo®（Nivolumab）联合化疗治疗经典型霍奇金淋巴瘤的申请给予优先审评。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BFXG1179.USD","LU0267386448.USD","LU1670711040.USD","LU0061475181.USD","LU1430594728.SGD","LU0225771236.USD","LU0985481810.HKD","IE00BFTCPJ56.SGD","LU0306806265.USD","LU0868494617.USD","LU1670710661.SGD","LU1718418525.SGD","BK4007","LU0237698245.USD","LU1074936037.SGD","LU2125154778.USD","BK4532","LU0321505868.SGD","BK4534","LU1670710588.SGD","LU1670711123.USD","LU1868836757.USD","LU1585245621.USD","LU1571399168.USD","LU0321505439.SGD","IE00B2B36J28.USD","BK4585","LU1323610961.USD","BK4581","LU1868836591.USD","LU2133065610.SGD","BMY","LU1261432733.SGD","BK4588","LU2242652126.USD","LU2242646821.SGD","LU1989771016.USD","IE00BSNM7G36.USD","LU0225284248.USD","LU0882574055.USD","LU1093756325.SGD","IE0002141913.USD","LU0456855351.SGD","LU2360032135.SGD","LU1868836914.USD","IE00BJT1NW94.SGD","IE0009355771.USD","LU2125154935.USD","LU1291159041.SGD","IE00BJJMRZ35.SGD","LU0114720955.EUR","LU1093756168.USD","LU1032466523.USD","LU1868837300.USD","LU0306807586.USD","LU0096364046.USD","LU1868837136.USD","BK4559"],"gpt_icon":0},{"id":"2590231598","title":"富国银行上调施贵宝目标价至55美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590231598","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590231598?lang=zh_cn&edition=full","pubTime":"2025-12-11 15:47","pubTimestamp":1765439222,"startTime":"0","endTime":"0","summary":"富国银行将施贵宝的目标价从53美元上调至55美元，维持“持有”评级。(格隆汇)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251211/31859114.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BMY"],"gpt_icon":0},{"id":"1103967501","title":"Biontech与施贵宝公布Pumitamig全球二期研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=1103967501","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1103967501?lang=zh_cn&edition=full","pubTime":"2025-12-09 20:18","pubTimestamp":1765282713,"startTime":"0","endTime":"0","summary":"12月9日（路透社）- BioNTech SE与施贵宝首次公布PD-L1XVEGF-A双特异性抗体Pumitamig在晚期三阴性乳腺癌中的全球二期研究数据，显示出令人鼓舞的疗效。Pumitamig联合化疗实现了61.5%的确认客观反应率、71.8%的未确认客观反应率和92.3%的疾病控制率，与PD-L1表达水平无关。这些数据与先前在中国进行的1L TNBC I期/II期临床试验中报告的数据一致，并确认了关键III期ROSETTA BREAST-01试验的剂量选择。相关数据将于2025年圣安东尼奥乳腺癌研讨会上公布。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0321505868.SGD","LU2242646821.SGD","LU0882574055.USD","LU1868837136.USD","IE00BJT1NW94.SGD","LU1093756325.SGD","BK4588","LU0237698245.USD","LU2125154935.USD","LU1989771016.USD","LU1032466523.USD","LU0456855351.SGD","LU1074936037.SGD","LU1291159041.SGD","BK4548","LU0267386448.USD","BK4581","BK4568","LU0868494617.USD","BK4585","IE00BFXG1179.USD","IE00BFTCPJ56.SGD","LU1670710661.SGD","LU2242652126.USD","LU2360032135.SGD","LU0306806265.USD","BK4534","LU0985481810.HKD","LU1868836591.USD","IE00BSNM7G36.USD","IE0009355771.USD","LU1718418525.SGD","BK4532","BK4551","LU1323610961.USD","LU0225771236.USD","BK4559","LU1261432733.SGD","LU1670711123.USD","BK4139","LU1430594728.SGD","LU2133065610.SGD","LU0061475181.USD","LU0114720955.EUR","BMY","LU1868836757.USD","LU2125154778.USD","LU1868837300.USD","LU0321505439.SGD","LU1585245621.USD","LU1670710588.SGD","LU1670711040.USD","BK4007","IE00BJJMRZ35.SGD","BNTX","LU1093756168.USD","LU1868836914.USD","BK4535","IE00B2B36J28.USD","IE0002141913.USD","LU0096364046.USD","LU0225284248.USD","LU1571399168.USD","LU0306807586.USD"],"gpt_icon":0},{"id":"1117454392","title":"BioNTech Se：Pumitamig联合化疗在所有四种化疗方案中的安全性均可控","url":"https://stock-news.laohu8.com/highlight/detail?id=1117454392","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1117454392?lang=zh_cn&edition=full","pubTime":"2025-12-09 20:04","pubTimestamp":1765281849,"startTime":"0","endTime":"0","summary":"BioNTech Se：Pumitamig联合化疗在所有四种化疗方案中均展现出可管理的安全性特征，且在两个队列中均表现良好。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BJJMRZ35.SGD","LU1571399168.USD","BK4585","LU1989771016.USD","LU0114720955.EUR","BK4559","BMY","IE00BFTCPJ56.SGD","LU1323610961.USD","BK4007","LU0306806265.USD","LU1670711040.USD","LU0306807586.USD","LU0882574055.USD","IE00B2B36J28.USD","LU0096364046.USD","LU2125154778.USD","IE00BFXG1179.USD","LU0321505439.SGD","LU1430594728.SGD","IE00BSNM7G36.USD","LU0321505868.SGD","LU1074936037.SGD","LU1093756168.USD","BK4532","LU1261432733.SGD","LU1670710661.SGD","LU0237698245.USD","LU1868837300.USD","LU1585245621.USD","LU2242652126.USD","IE0009355771.USD","LU2125154935.USD","LU2360032135.SGD","IE00BJT1NW94.SGD","LU0225771236.USD","LU2242646821.SGD","LU0225284248.USD","IE0002141913.USD","LU0456855351.SGD","LU0868494617.USD","LU1032466523.USD","LU0267386448.USD","LU0985481810.HKD","LU1868836914.USD","LU1670711123.USD","LU0061475181.USD","LU1868836591.USD","BK4588","BK4534","LU1868836757.USD","LU1718418525.SGD","BK4581","LU2133065610.SGD","LU1868837136.USD","LU1291159041.SGD","LU1670710588.SGD","LU1093756325.SGD"],"gpt_icon":0},{"id":"2588040563","title":"美股异动 | 百时美施贵宝(BMY.US)涨5% 公司将继续阿尔茨海默病研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2588040563","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588040563?lang=zh_cn&edition=full","pubTime":"2025-12-03 23:30","pubTimestamp":1764775808,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，周三，百时美施贵宝(BMY.US)涨5%，报50.67美元。消息面上，施贵宝周三表示，将招募更多参与者参加一项晚期试验，以评估Cobenfy治疗阿尔茨海默病痴呆相关精神病的安全性和有效性。该公司表示，在发现少数试验地点与临床研究执行相关的“不规范行为”后作出此决定，这些地点的患者数据将从主要分析中排除。据了解，Cobenfy目前已获批用于治疗成人精神分裂症，具有成为首个基于毒蕈碱受体激动作用、针对躁动和精神病的新一类药物疗法的潜力。预计ADEPT计划(包括ADEPT-2、ADEPT-1和ADEPT-4)针对阿尔茨海默病相关精神病的其他试验结果将在2026年底揭晓。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377514.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BMY","LU1670711040.USD","LU0225284248.USD","IE00BJT1NW94.SGD","LU1291159041.SGD","LU1868836757.USD","IE00BFXG1179.USD","LU1989771016.USD","LU0061475181.USD","LU1261432733.SGD","LU1571399168.USD","LU1868837136.USD","LU1670710661.SGD","BK4588","LU0267386448.USD","LU0321505439.SGD","LU2360032135.SGD","LU1323610961.USD","BK4532","LU1074936037.SGD","LU0882574055.USD","LU1585245621.USD","LU1868836591.USD","LU0096364046.USD","BK4581","IE00BJJMRZ35.SGD","LU1868836914.USD","LU2242646821.SGD","IE00BSNM7G36.USD","LU1093756325.SGD","LU1093756168.USD","IE0009355771.USD","IE0002141913.USD","LU2125154935.USD","LU0225771236.USD","BK4559","LU0114720955.EUR","BK4534","LU1670710588.SGD","LU0456855351.SGD","LU2133065610.SGD","LU0868494617.USD","LU0321505868.SGD","LU1430594728.SGD","LU2125154778.USD","LU1718418525.SGD","LU0985481810.HKD","LU0306806265.USD","IE00B2B36J28.USD","BK4585"],"gpt_icon":0},{"id":"1145973221","title":"施贵宝股价在盘前上涨3.4%，继续招募阿尔茨海默病药物试验患者","url":"https://stock-news.laohu8.com/highlight/detail?id=1145973221","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1145973221?lang=zh_cn&edition=full","pubTime":"2025-12-03 21:26","pubTimestamp":1764768379,"startTime":"0","endTime":"0","summary":"施贵宝股价在盘前上涨3.4%，继续招募阿尔茨海默病药物试验患者","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B2B36J28.USD","IE00BJT1NW94.SGD","LU0237698245.USD","IE00BSNM7G36.USD","LU0114720955.EUR","LU1032466523.USD","LU1868837300.USD","LU1989771016.USD","LU0321505868.SGD","BK4559","LU0882574055.USD","LU0225771236.USD","LU1670710588.SGD","LU1261432733.SGD","LU0456855351.SGD","LU1868836914.USD","IE00BFXG1179.USD","LU2125154935.USD","BMY","IE0009355771.USD","LU1291159041.SGD","BK4585","LU1868836591.USD","LU1093756325.SGD","LU1868836757.USD","LU1074936037.SGD","LU0321505439.SGD","LU1670711040.USD","LU2242652126.USD","BK4007","LU0306806265.USD","LU0225284248.USD","BK4581","BK4532","LU0061475181.USD","BK4588","LU1670710661.SGD","LU1718418525.SGD","LU1093756168.USD","LU1323610961.USD","IE00BFTCPJ56.SGD","IE00BJJMRZ35.SGD","BK4534","LU1571399168.USD","LU1430594728.SGD","LU2125154778.USD","LU2242646821.SGD","LU0985481810.HKD","LU1868837136.USD","LU0868494617.USD","LU1670711123.USD","LU2133065610.SGD","LU0096364046.USD","LU0306807586.USD","LU2360032135.SGD","LU1585245621.USD","IE0002141913.USD","LU0267386448.USD"],"gpt_icon":0},{"id":"2588046192","title":"百时美施贵宝将继续推进阿尔茨海默病药物三期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2588046192","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588046192?lang=zh_cn&edition=full","pubTime":"2025-12-03 20:59","pubTimestamp":1764766777,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU1868837300.USD","LU0868494617.USD","IE00B2B36J28.USD","BK4585","LU1261432733.SGD","LU1323610961.USD","LU1868836591.USD","LU2125154778.USD","LU1093756168.USD","LU1670711123.USD","LU1989771016.USD","IE00BJJMRZ35.SGD","LU0321505868.SGD","LU1868836914.USD","LU0114720955.EUR","BK4532","LU0985481810.HKD","LU0882574055.USD","LU0225771236.USD","IE0002141913.USD","LU1571399168.USD","LU1291159041.SGD","BK4581","IE00BFXG1179.USD","LU1093756325.SGD","LU1868836757.USD","BK4588","LU0237698245.USD","IE00BJT1NW94.SGD","LU0061475181.USD","LU0267386448.USD","LU1430594728.SGD","LU1585245621.USD","LU1670710661.SGD","LU1670710588.SGD","LU2125154935.USD","LU2242652126.USD","LU2133065610.SGD","LU2242646821.SGD","LU0306806265.USD","LU1074936037.SGD","LU1868837136.USD","IE0009355771.USD","IE00BSNM7G36.USD","LU1032466523.USD","BK4007","BMY","LU0456855351.SGD","BK4534","LU2360032135.SGD"],"gpt_icon":0},{"id":"1186291513","title":"施贵宝宣布继续进行针对阿尔茨海默病相关精神病的Adept-2三期研究","url":"https://stock-news.laohu8.com/highlight/detail?id=1186291513","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186291513?lang=zh_cn&edition=full","pubTime":"2025-12-03 19:59","pubTimestamp":1764763170,"startTime":"0","endTime":"0","summary":"施贵宝宣布继续进行针对阿尔茨海默病相关精神病的Adept-2三期研究","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0267386448.USD","LU0882574055.USD","LU1670711040.USD","LU2242652126.USD","LU1093756325.SGD","LU0114720955.EUR","LU1868837300.USD","IE00BFXG1179.USD","IE0009355771.USD","LU1093756168.USD","LU2360032135.SGD","BK4007","LU1670710661.SGD","LU1868836914.USD","LU0321505439.SGD","LU0321505868.SGD","IE0002141913.USD","BMY","LU2125154778.USD","LU2125154935.USD","LU1291159041.SGD","LU0456855351.SGD","BK4588","LU0061475181.USD","BK4532","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","LU1670710588.SGD","IE00B2B36J28.USD","LU0306807586.USD","BK4559","LU0306806265.USD","BK4585","LU1261432733.SGD","LU1323610961.USD","LU0868494617.USD","LU1571399168.USD","LU0985481810.HKD","LU1585245621.USD","LU1868836757.USD","LU0096364046.USD","IE00BJJMRZ35.SGD","BK4581","LU1074936037.SGD","LU1718418525.SGD","LU1868836591.USD","LU1868837136.USD","LU2242646821.SGD","LU1989771016.USD","LU0225771236.USD","LU1032466523.USD","LU0237698245.USD","LU0225284248.USD","BK4534","IE00BSNM7G36.USD","LU2133065610.SGD","LU1670711123.USD","LU1430594728.SGD"],"gpt_icon":0},{"id":"1187354797","title":"施贵宝CEO Boerner：施贵宝预计在英美制药交易后未来5年将能够投资超过5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=1187354797","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187354797?lang=zh_cn&edition=full","pubTime":"2025-12-01 22:56","pubTimestamp":1764600985,"startTime":"0","endTime":"0","summary":"施贵宝CEO Boerner表示，施贵宝预计在英美制药交易后，未来5年将能够投资超过5亿美元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868837300.USD","LU1430594728.SGD","LU2125154778.USD","LU0306806265.USD","LU1585245621.USD","BK4559","LU0321505868.SGD","BK4007","IE00BJT1NW94.SGD","BK4588","LU1868836914.USD","LU0225284248.USD","IE00BJJMRZ35.SGD","LU2242652126.USD","IE0009355771.USD","LU0267386448.USD","IE00B2B36J28.USD","LU0456855351.SGD","LU1093756168.USD","LU0306807586.USD","LU1074936037.SGD","BK4534","LU1868837136.USD","LU1093756325.SGD","LU2125154935.USD","LU0225771236.USD","IE00BFTCPJ56.SGD","LU1323610961.USD","LU1868836757.USD","BK4532","LU0061475181.USD","LU1032466523.USD","LU0985481810.HKD","LU2242646821.SGD","IE00BSNM7G36.USD","BMY","IE0002141913.USD","LU1868836591.USD","LU1989771016.USD","LU1261432733.SGD","BK4585","LU1718418525.SGD","LU2133065610.SGD","LU1571399168.USD","LU0321505439.SGD","LU1670710661.SGD","LU1670711040.USD","LU1670711123.USD","LU0237698245.USD","LU1670710588.SGD","LU0096364046.USD","BK4581","LU0868494617.USD","LU2360032135.SGD","LU0114720955.EUR","LU0882574055.USD","LU1291159041.SGD","IE00BFXG1179.USD"],"gpt_icon":0},{"id":"1154511184","title":"施贵宝在2025年ASH大会上展示血液学管线潜力，推动下一代产品组合的动能","url":"https://stock-news.laohu8.com/highlight/detail?id=1154511184","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1154511184?lang=zh_cn&edition=full","pubTime":"2025-12-01 20:00","pubTimestamp":1764590411,"startTime":"0","endTime":"0","summary":"施贵宝在2025年ASH大会上展示血液学管线潜力，推动下一代产品组合的动能","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868837300.USD","LU1430594728.SGD","LU2125154778.USD","LU0306806265.USD","LU1585245621.USD","BK4559","LU0321505868.SGD","BK4007","IE00BJT1NW94.SGD","BK4588","LU1868836914.USD","LU0225284248.USD","IE00BJJMRZ35.SGD","LU2242652126.USD","IE0009355771.USD","LU0267386448.USD","IE00B2B36J28.USD","LU0456855351.SGD","LU1093756168.USD","LU0306807586.USD","LU1074936037.SGD","BK4534","LU1868837136.USD","LU1093756325.SGD","LU2125154935.USD","LU0225771236.USD","IE00BFTCPJ56.SGD","LU1323610961.USD","LU1868836757.USD","BK4532","LU0061475181.USD","LU1032466523.USD","LU0985481810.HKD","LU2242646821.SGD","IE00BSNM7G36.USD","BMY","IE0002141913.USD","LU1868836591.USD","LU1989771016.USD","LU1261432733.SGD","BK4585","LU1718418525.SGD","LU2133065610.SGD","LU1571399168.USD","LU0321505439.SGD","LU1670710661.SGD","LU1670711040.USD","LU1670711123.USD","LU0237698245.USD","LU1670710588.SGD","LU0096364046.USD","BK4581","LU0868494617.USD","LU2360032135.SGD","LU0114720955.EUR","LU0882574055.USD","LU1291159041.SGD","IE00BFXG1179.USD"],"gpt_icon":0},{"id":"1197403315","title":"四川百利天恒表示仍有资格获得高达2.5亿美元的短期付款，以及在达到特定研发、监管、商业里程碑后获得高达71亿美元的额外付款","url":"https://stock-news.laohu8.com/highlight/detail?id=1197403315","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1197403315?lang=zh_cn&edition=full","pubTime":"2025-11-30 17:18","pubTimestamp":1764494292,"startTime":"0","endTime":"0","summary":"四川百利天恒表示仍有资格获得高达2.5亿美元的短期付款，以及在达到特定研发、监管、商业里程碑后获得高达71亿美元的额外付款。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4559","LU1093756325.SGD","LU1868836591.USD","IE0002141913.USD","IE0009355771.USD","LU1670711123.USD","LU1868836757.USD","LU0306807586.USD","LU1670711040.USD","IE00B2B36J28.USD","LU1074936037.SGD","LU0267386448.USD","BK4585","BK4581","LU0114720955.EUR","LU2125154778.USD","LU0225284248.USD","688506","BK4532","LU1430594728.SGD","LU0225771236.USD","LU0321505868.SGD","LU2360032135.SGD","LU1323610961.USD","LU2242652126.USD","LU1670710661.SGD","BMY","LU2242646821.SGD","LU0985481810.HKD","LU1670710588.SGD","LU1093756168.USD","LU2125154935.USD","LU0882574055.USD","LU1571399168.USD","LU1261432733.SGD","BK0239","LU0456855351.SGD","LU1868836914.USD","LU1868837300.USD","IE00BJT1NW94.SGD","LU0306806265.USD","LU1032466523.USD","LU1868837136.USD","LU0096364046.USD","IE00BJJMRZ35.SGD","IE00BSNM7G36.USD","LU0868494617.USD","LU1718418525.SGD","BK4534","BK4007","LU0321505439.SGD","LU2133065610.SGD","LU1291159041.SGD","LU1989771016.USD","BK4588","LU1585245621.USD","LU0061475181.USD","IE00BFTCPJ56.SGD","IE00BFXG1179.USD","LU0237698245.USD"],"gpt_icon":0},{"id":"1112180261","title":"百利天恒宣布其子公司近期已从施贵宝获得2.5亿美元里程碑付款，涉及Iza-Bren全球战略协议","url":"https://stock-news.laohu8.com/highlight/detail?id=1112180261","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112180261?lang=zh_cn&edition=full","pubTime":"2025-11-30 17:18","pubTimestamp":1764494292,"startTime":"0","endTime":"0","summary":"百利天恒宣布其子公司近期已从施贵宝获得2.5亿美元的里程碑付款，涉及Iza-Bren全球战略协议。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0306807586.USD","LU1868837300.USD","LU0868494617.USD","LU0321505439.SGD","IE00B2B36J28.USD","BK4585","LU1261432733.SGD","LU1323610961.USD","LU1868836591.USD","LU2125154778.USD","LU0225284248.USD","LU1093756168.USD","LU1670711123.USD","LU1989771016.USD","IE00BJJMRZ35.SGD","LU0321505868.SGD","LU0096364046.USD","LU1868836914.USD","LU0114720955.EUR","BK4532","LU0985481810.HKD","LU0882574055.USD","LU0225771236.USD","IE0002141913.USD","LU1571399168.USD","LU1718418525.SGD","LU1291159041.SGD","BK4581","IE00BFXG1179.USD","BK4559","LU1093756325.SGD","BK4588","LU0237698245.USD","IE00BJT1NW94.SGD","LU1868836757.USD","LU0061475181.USD","LU0267386448.USD","IE00BFTCPJ56.SGD","LU1430594728.SGD","LU1585245621.USD","LU1670710661.SGD","LU1670710588.SGD","LU2125154935.USD","LU2242652126.USD","BK0239","LU2133065610.SGD","LU2242646821.SGD","LU0306806265.USD","LU1670711040.USD","LU1074936037.SGD","LU1868837136.USD","IE0009355771.USD","IE00BSNM7G36.USD","LU1032466523.USD","BK4007","BMY","LU0456855351.SGD","BK4534","688506","LU2360032135.SGD"],"gpt_icon":0},{"id":"2587799680","title":"百利天恒(688506.SH)子公司收到与百时美施贵宝就iza-bren项目里程碑付款2.5亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2587799680","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2587799680?lang=zh_cn&edition=full","pubTime":"2025-11-30 16:56","pubTimestamp":1764492983,"startTime":"0","endTime":"0","summary":"智通财经APP讯，百利天恒(688506.SH)发布公告，公司全资子公司SystImmune近期收到由BMS支付的2.5亿美元里程碑付款。根据合作协议，公司后续还有资格获得最高可达2.5亿美元的近期或有付款，以及在达到特定的开发、注册和销售里程碑后最高可达71亿美元的额外付款。合作协议中所约定的里程碑付款需要满足一定的条件，最终里程碑付款尚存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1375666.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IE00BJJMRZ35.SGD","LU1074936037.SGD","LU1323610961.USD","BK4585","LU1868836914.USD","LU0225771236.USD","LU0321505439.SGD","LU1093756325.SGD","688506","LU0985481810.HKD","IE00BSNM7G36.USD","LU0267386448.USD","BK4588","BK0239","LU1093756168.USD","LU2242652126.USD","LU1868837136.USD","IE00BJT1NW94.SGD","BK4581","LU1585245621.USD","LU1261432733.SGD","IE00B2B36J28.USD","BK4559","BK4532","LU1868837300.USD","91194","BK4007","LU0306806265.USD","LU0096364046.USD","IE0002141913.USD","LU1868836591.USD","LU2360032135.SGD","LU1670710588.SGD","LU2133065610.SGD","IE00BFTCPJ56.SGD","LU1430594728.SGD","LU2125154935.USD","LU2242646821.SGD","LU1670710661.SGD","LU0882574055.USD","LU1718418525.SGD","LU0306807586.USD","BMY","LU0114720955.EUR","LU1670711123.USD","LU1868836757.USD","02615","LU1032466523.USD","LU0868494617.USD","LU1291159041.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.bms.com","stockEarnings":[{"period":"1week","weight":0.0707},{"period":"1month","weight":0.1625},{"period":"3month","weight":0.1751},{"period":"6month","weight":0.1578},{"period":"1year","weight":-0.0294},{"period":"ytd","weight":-0.0412}],"compareEarnings":[{"period":"1week","weight":-0.0061},{"period":"1month","weight":0.0103},{"period":"3month","weight":0.0299},{"period":"6month","weight":0.1363},{"period":"1year","weight":0.1188},{"period":"ytd","weight":0.1583}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"百时美施贵宝公司于1933年8月根据特拉华州法律注册成立，名为百时美公司，继承了1887年在纽约成立的一家企业。1989年，由于合并，公司更名为百时美施贵宝公司。该公司在全球范围内从事生物制药产品的发现、开发、许可、制造、营销、分销和销售。该公司预计，对Celgene和MyoKardia的收购将进一步将公司定位为领先的生物制药公司，通过几项近期资产和额外的外部合作伙伴关系扩大其肿瘤学、血液学、免疫学和心血管领域的投资组合。","yearOnYearQuotes":[{"month":1,"riseRate":0.466667,"avgChangeRate":-0.012031},{"month":2,"riseRate":0.555556,"avgChangeRate":0.009164},{"month":3,"riseRate":0.644444,"avgChangeRate":0.008753},{"month":4,"riseRate":0.478261,"avgChangeRate":-0.005913},{"month":5,"riseRate":0.565217,"avgChangeRate":0.002647},{"month":6,"riseRate":0.608696,"avgChangeRate":0.009417},{"month":7,"riseRate":0.413043,"avgChangeRate":-0.001733},{"month":8,"riseRate":0.521739,"avgChangeRate":-0.001022},{"month":9,"riseRate":0.521739,"avgChangeRate":0.00993},{"month":10,"riseRate":0.586957,"avgChangeRate":0.025121},{"month":11,"riseRate":0.630435,"avgChangeRate":0.022318},{"month":12,"riseRate":0.630435,"avgChangeRate":0.022393}],"exchange":"NYSE","name":"施贵宝","nameEN":"Bristol-Myers Squibb"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"施贵宝,BMY,施贵宝股票,施贵宝股票老虎,施贵宝股票老虎国际,施贵宝行情,施贵宝股票行情,施贵宝股价,施贵宝股市,施贵宝股票价格,施贵宝股票交易,施贵宝股票购买,施贵宝股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"施贵宝(BMY)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供施贵宝(BMY)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}